申请人:Pfizer Inc.
公开号:US20210017205A1
公开(公告)日:2021-01-21
The present invention is directed to a new fluoro-pyridinone hydroxamic acid phosphates and boronates of Formulae I, II and III
wherein Q is selected from the group consisting of —P(O)(OH)
2
, —P(O)(OH)(O
−
M
+
), —P(O)(O
−
M
+
)
2
and —P(O)(O
−
)
2
M
2+
; M
+
at each occurrence is a pharmaceutically acceptable monovalent cation; and M
2+
is a pharmaceutically acceptable divalent cation and their use as LpxC inhibitors and, more specifically, their use to treat bacterial infections.